Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults.

Front Oncol · 2023 · PMC10533987 · PMID 37781183

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Everolimus showed a trend towards better efficacy (not statistically significant) when compared to erlotinib and dasatinib, with a good toxicity profile.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.